Selective inhibitor of KDM5 demethylases (IC50 value 10 nM for inhibition of full length KDM5A) that specifically alters H3K4 methylation in several cell contexts and reduces survival of drug-tolerant cancer cells. CPI-455 possesses the target specificity required for an in vitro tool compound for exploring KDM5-dependent disease biology, including drug tolerance.

Note: CPI 455 can be used in combination with a less potent control compound, by the authors of the 2016 Nature publication referred to as CPI 4203 (Axon 2622). 

KEYWORDS: CPI 455 | supplier | KDM5 inhibitor | CPI455 | CAS [1628208-23-0] | Histone demethylase | Inhibitor | H3K4 | KDM5A | lysine | methylation | drug tolerance | cancer | DTP | SET-domain